JP2021529165A5 - - Google Patents

Info

Publication number
JP2021529165A5
JP2021529165A5 JP2020570554A JP2020570554A JP2021529165A5 JP 2021529165 A5 JP2021529165 A5 JP 2021529165A5 JP 2020570554 A JP2020570554 A JP 2020570554A JP 2020570554 A JP2020570554 A JP 2020570554A JP 2021529165 A5 JP2021529165 A5 JP 2021529165A5
Authority
JP
Japan
Prior art keywords
teverelix
composition
tfa
trifluoroacetate
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570554A
Other languages
English (en)
Japanese (ja)
Other versions
JP7181318B2 (ja
JP2021529165A (ja
Filing date
Publication date
Priority claimed from EP18181945.9A external-priority patent/EP3590525A1/en
Application filed filed Critical
Publication of JP2021529165A publication Critical patent/JP2021529165A/ja
Publication of JP2021529165A5 publication Critical patent/JP2021529165A5/ja
Priority to JP2022183797A priority Critical patent/JP2023027082A/ja
Application granted granted Critical
Publication of JP7181318B2 publication Critical patent/JP7181318B2/ja
Priority to JP2024159884A priority patent/JP2025004006A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570554A 2018-07-05 2019-07-02 テベレリクス－ｔｆａ組成物 Active JP7181318B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022183797A JP2023027082A (ja) 2018-07-05 2022-11-17 テベレリクス－ｔｆａ組成物
JP2024159884A JP2025004006A (ja) 2018-07-05 2024-09-17 テベレリクス－ｔｆａ組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18181945.9A EP3590525A1 (en) 2018-07-05 2018-07-05 Teverelix-tfa composition
EP18181945.9 2018-07-05
PCT/EP2019/067728 WO2020007857A1 (en) 2018-07-05 2019-07-02 Teverelix-tfa composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183797A Division JP2023027082A (ja) 2018-07-05 2022-11-17 テベレリクス－ｔｆａ組成物

Publications (3)

Publication Number Publication Date
JP2021529165A JP2021529165A (ja) 2021-10-28
JP2021529165A5 true JP2021529165A5 (https=) 2022-06-14
JP7181318B2 JP7181318B2 (ja) 2022-11-30

Family

ID=62874669

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020570554A Active JP7181318B2 (ja) 2018-07-05 2019-07-02 テベレリクス－ｔｆａ組成物
JP2022183797A Withdrawn JP2023027082A (ja) 2018-07-05 2022-11-17 テベレリクス－ｔｆａ組成物
JP2024159884A Pending JP2025004006A (ja) 2018-07-05 2024-09-17 テベレリクス－ｔｆａ組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022183797A Withdrawn JP2023027082A (ja) 2018-07-05 2022-11-17 テベレリクス－ｔｆａ組成物
JP2024159884A Pending JP2025004006A (ja) 2018-07-05 2024-09-17 テベレリクス－ｔｆａ組成物

Country Status (6)

Country Link
US (2) US11357818B2 (https=)
EP (3) EP3590525A1 (https=)
JP (3) JP7181318B2 (https=)
CN (2) CN118161591A (https=)
CA (1) CA3141519A1 (https=)
WO (1) WO2020007857A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
EP4541365A1 (en) 2023-10-18 2025-04-23 Antev Limited Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer
EP4643869A1 (en) 2024-05-03 2025-11-05 Antev Limited Use of gnrh antagonists such as teverelix to treat acute urinary retention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985723A (en) * 1971-09-07 1976-10-12 The University Of Mississippi Trifluoroacetylation process
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2008071984A1 (en) * 2006-12-13 2008-06-19 Ardana Bioscience Limited Administration of the gonadotropin-releasing hormone antagonist teverelix
CN105693844A (zh) * 2016-03-10 2016-06-22 泰州施美康多肽药物技术有限公司 一种促性腺激素释放激素类似物醋酸盐的制备方法
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Similar Documents

Publication Publication Date Title
JP2021529165A5 (https=)
ES2260916T3 (es) Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica.
JP2011225581A5 (https=)
JP2013513559A5 (https=)
JP2019529574A5 (https=)
Zhang et al. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81–95 peptide show effective antitumor activity against ovarian carcinoma
RU2013120311A (ru) Терапевтическое применение агониста tlr и комбинированная терапия
JP2009102342A5 (https=)
ES2338217T3 (es) Antagonistas de la hormona liberadora de gonadotrpina en concentraciones formadoras de gel.
JP2020143143A (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
JP2003206240A5 (https=)
RU2004102507A (ru) Композиция с регулируемым высвобождением и способ ее получения
JP2005511491A5 (https=)
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
KR20120015310A (ko) 전립선암 치료용 조성물
RU2015106791A (ru) Иммуногенные композиции
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
RU2004102503A (ru) Композиция пролонгированного действия и способ получения указанной композиции
JP2020524670A5 (https=)
JP2018138596A5 (https=)
JP2025004006A (ja) テベレリクス－ｔｆａ組成物
CN115803055A (zh) 一种抗pd-1单克隆抗体液体制剂
ES2938772T3 (es) Composición farmacéutica para la prevención o el tratamiento de la onicomicosis y método de preparación de la misma
ES2235967T3 (es) Composicion hormonal a base de acetato de nomegestrol y de un estrogeno y su utilizacion.
JP2012525358A5 (https=)